Literature DB >> 19022709

Some important considerations for validation of ligand-binding assays.

John W A Findlay1.   

Abstract

Calibration curves for ligand-binding assays (LBAs) are inherently non-linear and standard curve fitting algorithms require careful selection. Reference standards for macromolecule LBAs are more complex than are low-molecular-weight reference standards. Specificity of small molecule LBAs, and accuracy of reported study sample data are easier to assess by cross-validation with a chromatographic method than for macromolecule LBAs. Due to the lack of knowledge of the potential interference of unknown products of catabolism, proteolysis or biotransformation of macromolecules (particularly proteins) in LBAs for the parent molecule, the accuracy of reported concentrations and derived pharmacokinetic data for macromolecules, as determined by LBA, should be viewed with caution. In validation of LBAs, the total error and confidence interval approaches to assessment of the acceptability of an assay for routine implementation for the desired purpose should be given due consideration.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19022709     DOI: 10.1016/j.jchromb.2008.10.045

Source DB:  PubMed          Journal:  J Chromatogr B Analyt Technol Biomed Life Sci        ISSN: 1570-0232            Impact factor:   3.205


  4 in total

Review 1.  Fit-for-purpose biomarker method validation for application in clinical trials of anticancer drugs.

Authors:  J Cummings; F Raynaud; L Jones; R Sugar; C Dive
Journal:  Br J Cancer       Date:  2010-10-05       Impact factor: 7.640

2.  Issues on fit-for-purpose validation of a panel of ELISAs for application as biomarkers in clinical trials of anti-Angiogenic drugs.

Authors:  K Brookes; J Cummings; A Backen; A Greystoke; T Ward; G C Jayson; C Dive
Journal:  Br J Cancer       Date:  2010-04-20       Impact factor: 7.640

3.  Method validation of circulating tumour cell enumeration at low cell counts.

Authors:  Jeffrey Cummings; Karen Morris; Cong Zhou; Robert Sloane; Matt Lancashire; Daniel Morris; Stephen Bramley; Matt Krebs; Leila Khoja; Caroline Dive
Journal:  BMC Cancer       Date:  2013-09-11       Impact factor: 4.430

4.  Improvements to Hybridization-Ligation ELISA Methods to Overcome Bioanalytical Challenges Posed by Novel Oligonucleotide Therapeutics.

Authors:  Joseph A Haegele; Ramakrishna Boyanapalli; Jaya Goyal
Journal:  Nucleic Acid Ther       Date:  2022-04-11       Impact factor: 4.244

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.